Aim: The association between parity and rheumatoid arthritis (RA) risk has been investigated, but results are controversial. Thus, our aim was to systematically analyze the effect of number of parity on the risk of RA in women. Methods: Relevant published studies were identified using PUBMED and EMBASE databases through 1 April 2016. We pooled the relative risks (RR) and 95% confidence intervals (CI) using random-effects models. Results: In all, 12 studies with a total of 2 497 580 participants and 11 521 RA cases were included. A borderline significant inverse association was observed when we compared parity with nulliparity for RA, with summarized RR = 0.90 (95%CI: 0.79-1.02; I 2 = 58.5%, Pheterogeneity = 0.010). In dose-response analysis, we observed a significant nonlinear (Pnonlinearity = 0.000) relation between parity number and the risk of RA. 
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by systemic features and joint involvement, affecting 1% of the world's adults. 1 It primarily affects women, with females having more than a twofold higher incidence of RA than males. 1 RA patients continue to face steep rises in the burden of disease, with disability-adjusted life year estimates increased from 3.3 million in 1990 to 4.8 million in 2010. Globally, RA ranks as the 42nd highest contributor to global disability. 2 The prevention of RA is thus clearly an important public health priority.
Many common risk factors can increase the initiation and promotion of RA, such as genes, age, sex, alcohol, cigarette smoking, and dietary habits. [3] [4] [5] [6] Parity is an important factor for women and is associated with many diseases, such as thyroid cancer, kidney cancer, gallbladder cancer, and type-II diabetes. [7] [8] [9] [10] Epidemiological studies are increasingly focusing on whether reproductive factors among women may be related to a risk of developing RA. Yet, varying evidence has presented conflicting results. Recent evidence from epidemiological studies has suggested that reproductive factors may be an important protective factor for the development of RA. 11, 12 A population-based study in the state of Washington, USA, confirmed that parity of any number, compared to nulliparity, was significantly associated with a lower risk of RA (RR 0.61, 95%CI: 0.43-0.86, P = 0.005). 11 Similarly, in another populationbased study, an inverse association was also observed between parity and risk of RA. 12 However, other studies have found weak or null associations between them. 13, 14 Thus, the findings on this topic remain unclear. Moreover, no systematic review has evaluated the effects of parity number for patients with RA.
Hence, to investigate the association between parity number and the risk of RA, we performed a rigorous systematic review and dose-response metaanalysis.
Methods
This current meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines. 15, 16 There is no ethical issue involved in our data for this meta-analysis.
Search strategy
We searched two databases (PUBMED and EMBASE) with the key words and Medical Subject Headings ('parity,' 'multi-parity,' 'pregnancy,' 'reproductive,' 'reproduction,' 'fertility,' and 'delivery') in combination with 'rheumatoid arthritis' through 1 April 2016. No language or any other restrictions were set in the search strategy. To identify potential publications, the additional articles were obtained through consulting the reference lists of relevant studies. We contacted the corresponding authors of certain articles if more data were required.
Study selection
Studies were included in this meta-analysis if they satisfied the following inclusion criteria: (i) the association between parity and risk of RA was evaluated; (ii) a cohort or case-control study design was used; (iii) the value of relative risk (RR), mortality relative risk (MRR), or odds ratio (OR) with 95% confidence intervals (CI) or enough data to calculate them were reported; and (iv) studies included for doseresponse meta-analysis with restricted cubic splines required at least three categories. When different articles from the same dataset were obtained, only the most recent study with available data was included. If multiple publications from the same population were identified, we included the study with the largest number of cases and most relevant information. 17 
Data extraction
The data of each article were extracted by two reviewers (C.Y. and H.Y.) independently, and any discrepancy was crosschecked again and resolved through discussion. The following data was extracted from each article: name of the first author, publication year, study design, geographical location, age range, duration of followup, sample size, parity categories, and OR/RR/MRR value with 95%CI and adjustments of the confounding factors.
Quality assessment
The study quality was assessed by two authors (S.Q.M. and L.H.) back-to-back and any disagreement was discussed with the third author (R.L.). Considering the observational study design of the included studies, we used the Newcastle-Ottawa Scale (NOS) to assess the methodological quality of the studies included. 18, 19 The NOS assessed the selection, comparability, and exposure of a case-control study and the outcome of a cohort study. A maximum of nine stars was scored for a study and a study with more than seven stars would be regarded as relatively high-quality.
Statistical analysis
STATA (version 12.0, Stata Corp) was used to conduct the meta-analysis. The RR was applied as a measure of the effect size. Two-tailed P-values < 0.05 were considered statistically significant. A random-effects model was applied to estimate the pooled effects for a more conservative conclusion.
After the preliminary experiment, we first summarized the RR for ever parity versus nulliparity on RA in the included studies in the initial meta-analysis. Further, to use all disease-exposure information, including any categories, we performed a two-stage dose-response meta-analysis. The methods described by Greenland et al. 20 and Orsini et al. 21 were used for the dose-response analysis. For this procedure, we examined a potential nonlinear dose-response relation between parity and RA risk using restricted cubic splines with three knots at percentiles 10%, 50%, and 90% of the distribution. [21] [22] [23] A P-value for nonlinearity was calculated by testing the null hypothesis that the coefficient of the second spline is equal to 0. If a nonlinear dose-response trend was not detected, we explored a linear trend using the same function. 24 For each of the included studies, we assigned the reported median or mean number of parity of each category as the category number of parity. When the lowest category was open-ended, the lowest boundary was set to zero. When the highest category was open-ended, its category number of parity was calculated as the lower bound plus 1.5 times the width of the closest category.
Heterogeneity among the included studies was detected by both Cochran's Q and I 2 statistics. 25 When P for the heterogeneity <0.1 and I 2 > 50%, the heterogeneity would be considered statistically significant. Subgroup and regression analyses were performed to explore sources of heterogeneity. We carried out sensitivity analyses excluding one study at a time to explore whether the results were strongly influenced by a specific study. 26 The potential publication bias was evaluated using Egger's linear regression 27 and Begg's rank correlation method. 28 If publication bias was detected, we used the trim and fill method to further evaluate the bias. EMBASE) were identified from the electronic database searching. No new study was identified through consulting the reference lists of the relevant reviews and articles. After omitting the duplicate, 5812 records were assessed further. After excluding 5727 records at the title and abstract level, a total of 85 full-texts were evaluated in detail. Via carefully scanning, 15 full-texts were assessed for eligibility after removing 70 articles (reviews, case reports, and overlapped articles). Subsequently, three articles duplicated the same study populations and four articles were excluded due to insufficient data. Eventually, a total of 12 studies [11] [12] [13] [14] [30] [31] [32] [33] [34] [35] [36] [37] were included for the quantitative synthesis (Fig. 1) .
Study characteristics
Of the 12 studies, a total of 11 521 cases and 2 497 580 individuals were incorporated in this meta-analysis. All the detailed characteristics of each study are presented in Table 1. 11 -14,30-37 The included studies were published between 1990 and 2014. A total of six cohort studies 13 
Study quality
The NOS scores of each part in the evaluation of all the studies are displayed in Table 2a-b. 3,11-14,30-33,35-37 Most studies 30, 32, 34, 36, 37 adjusted for important confounding factors, such as age, smoking, oral contraceptive use, and age at birth of first child. Five in 12 studies were in relatively high-quality (more than seven stars). One study achieved just five stars due to its low rate of follow-up. 14 
Ever parity versus nulliparity analysis
Six cohort studies 13, 14, [34] [35] [36] [37] and four case-control studies 11, 12, 30, 33 were focused on the relation between ever parity and the risk of RA. The summary RR of RA for ever parity compared with nulliparity was 0.90 (95%CI: 0.79-1.02), with moderate heterogeneity (Q = 21.71, I 2 = 58.5%, Pheterogeneitty = 0.010, Fig. 2 ). years, a point was assigned. ¶If the completeness of follow-up was 80% or more, a point was assigned.
Dose-response analysis
Six cohort studies 13, 14, [34] [35] [36] [37] and five case-control studies 11, 12, [31] [32] [33] were conducted in the dose-response analysis.
A significant nonlinear relation (Pnonlinearity = 0.000) between parity number and RA risk was observed via using restricted cubic splines. (Fig. 3) .
To reflex the local fluctuation of the relation between parity and RA risk, four knots at percentiles 5%, 35%, 65%, and 95% of the distribution were used and the significant nonlinear relation (Pnonlinearity = 0.000) was still obtained. Further, after excluding the casecontrol studies 11, 12, [30] [31] [32] [33] and each study one by one, we detected a similar result (data not shown).
Subgroup and meta-regression analyses
The results of the subgroup and regression analyses are presented in Table 3 . Then, in subgroup analyses, the data were reanalyzed and stratified by study type, geographic location, study quality, study population, cigarette smoking, oral contraceptive use, breastfeeding, and age at first birth. In the subgroup analyses of parity and RA risk, majority strata do not change the association, which are in the same direction with primary results. Only in the low-study-quality subgroup could we find a significant difference among the summarized results of the studies, which might be partially responsible for the significant heterogeneity of the main result. Additionally, the meta-regression analyses did not reveal the interaction effect between subgroups (P > 0.05).
Sensitivity analysis
The influence of a single study on the overall result was estimated. The 10 study-specific RR of ever parity versus nulliparity ranged from a low of 0.86 (95%CI: 0.76-0.98) after omission of the study by Heliovaara et al. 36 to a high of 0.94 (95%CI: 0.84-1.04) after omission of the study by Guthrie et al.
11

Table 2b
Methodological quality of the included case-control studies, based on the Newcastle-Ottawa Scale for assessing the quality of observational studies 
Publication bias
There was no indication of publication bias with Egger's test (P for bias = 0.396) or with Begg's test (P for bias = 0.283) and no asymmetry was observed in the funnel plots when inspected visually.
Discussion Main findings
We primarily comprehensively and quantitatively evaluated the relation between parity and the risk of RA. The traditional qualitative meta-analysis suggests a borderline significantly reduced risk of RA in cases of ever parity versus nulliparity (RR = 0.90, 95%CI: 0.79-1.02). However, a different dose-response analysis reveals a significant J-shaped relation between parity number and RA risk, which can more precisely disclose the real relation of them. Sensitivity analysis shows consistent results, which support our finding.
Results in relation to other studies
Compared to nulliparity, our dose-response metaanalysis shows that ever parity has a significantly protective effect against the risk of RA, which was in line with the results of most previous original studies on this topic. For example, Guthrie et al. 11 reported a significant reduction of RA risk associated with parity (RR = 0.61, 95%CI: 0.43-0.86). Additionally, Peschken et al.
12 also hold that greater parity significantly reduced the odds of RA, which was similar to the findings of the present meta-analysis. However, a few studies provide a null association between parity and RA due to some confounders that were not adjusted.
14,35,37
Possible mechanism
Our study suggests a J-shaped association between parity and RA risk. Why not linear associations? The exact biologic mechanisms are not fully clear, but several potential mechanisms might be involved, as suggested in the following list. 1 As we all know, hormones (estrogen, progesterone, corticoids) increase throughout pregnancy. 38, 39 Estrogen can decrease the stromal cell production of interleukin (IL)-1, IL-6, and tumor necrosis factor-α, which are centrally pathognomonic in the pathogenesis of RA. 40 Progesterone can maintain pregnancy by decreasing T-cell response, which may also contribute to amelioration of RA during pregnancy. 41 Corticoids are well known to exert various important antiinflammatory and immunosuppressant actions. 42 Numerous pregnancies result in prolonged exposure to high levels of estrogen, progesterone, and corticoids, which may reduce the risk of RA.
2 During human pregnancy, cell-mediated and humoral immunity changes occur, which can ameliorate RA via the immune tolerance pattern. [43] [44] [45] 3 Women who have had at least one live birth are more likely to have healthy behaviors, such as smoking less, drinking less, and exercising more compared with those with no live births. [46] [47] [48] Such healthy behaviors may contribute to the reduced risk of RA.
4 Specific human leukocyte antigen (HLA) II alleles are associated with RA risk and others with protection. 49 Risk-associated alleles encode similar amino acid sequences from 70 through 74 of HLA-DRβ1 (QKRAA, QRRAA, RRRAA), referred to as the 'shared epitope' (SE) and protective alleles encode DERAA at the same location. 50, 51 Fetal-maternal cell exchange results in long-term microchimerism (i.e., harboring small numbers of genetically disparate cells). Women who lacked SE or DERAA were found to harbor microchimerism with the SE or DERAA via fetal-maternal cell exchange. 49, 52, 53 Guthrie et al.
49
raised a logical hypothesis: There are inherent tradeoffs from parity for women, with the possibility to acquire both protection and risk but with protection Nevertheless, the increase in RA risk with increasing parity after two children may be the result of accumulative physiological and lifestyle changes, as suggested in the following list.
1 Numerous pregnancies result in prolonged exposure to high levels of estrogen and progesterone, which may reduce the risk of RA. However, numerous pregnancies also relate to older maternal age, inflammation, and oxidative stress, 54 which are closely associated with adverse predictors for RA. As we all know, with increased age, ovarian function gradually degrades, and hormone levels decrease, which lowers hormonal protection. Meanwhile, age is an independent risk factor for many diseases.
2 Increased risk of RA is more likely to be attributable to lifestyle factors, such as anxiety, work stress, 55 and even fear of raising children. A prospective Finnish study suggests that work stress may increase the risk of RA. 55 3 Socioeconomic factors may also enhance the relation between parity and RA, 56, 57 because both RA and high parity have higher frequency in lower social classes. A result from the Swedish EIRA study suggests that high socioeconomic status has a lower risk of RA. 56 This could partly explain the upstage of the J-shaped association between parity and RA.
Therefore, the cumulative effect of these adaptations and risks may contribute to the above-noted J-shaped association between parity and RA risk, not the linear associations. Nevertheless, the exact mechanisms about parity and RA merit further investigation.
In addition, we have also tried our best to identify the possible genetic disturbances of parous and nulliparous women. Surprisingly, we found that the effect of parity varied according to a woman's HLA-genotype. The research by Guthrie et al. 49 shows that among women with the SE and thus at increased risk for RA, parous women were at significantly lower risk compared to nulliparous women (RR 0.42; 95%CI: 0.22-0.79). Parity was significantly associated with lower risk of RA among women lacking the DERAA sequence (RR 0.44; 95%CI: 0.26-0.74). The results indicate that nulliparous women who possess the SE or lack the DERAA sequence in their HLA-genotype were at higher risk compared to parous women. That is to say, parity may be more beneficial to women who possess the SE or lack the DERAA sequence in their HLA-genotype.
Exploration of heterogeneity
In our meta-analysis, some heterogeneity was observed. Therefore, potential confounders, such as study type, geographic location, study quality, study population, cigarette smoking, oral contraceptive use, breastfeeding, and age at first birth were chosen to conduct subgroup analysis, and the results were not influenced significantly. Furthermore, there was no evidence of significant heterogeneity between subgroups with meta-regression analyses, which suggests that our results were not affected by between-study interaction. In sensitivity analyses, the inverse nonlinear association between parity and RA was still obtained and a series of subgroup, sensitivity analyses suggests that the credibility of the results is high.
Strengths and limitations
Our meta-analysis has several strengths. First, to the best of our knowledge, this is the first meta-analysis investigating the relation between parity and RA risk and conducting a dose-response analysis to further understand their inherent association. Second, our study was conducted based on 11 521 cases and 2 497 580 participants, which generated a stronger statistical power for us to detect and verify this putative association. Third, to confirm the robustness of the results, a series of sensitivity analyses, subgroup and meta-regression analyses showed robust combined estimates, and publication bias was not observed for the different statistical analyses. However, although outcome evidence from long-term randomized trials is ideal, these studies are too difficult to implement on a practical basis, especially concerning reproductive factors.
Meanwhile, several limitations should also be acknowledged. First, case-control studies were included, which have inherent methodological flaws, such as recall bias, selection bias, and reliability of exposure information. Therefore, the results should be interpreted with caution. However, our rigorous analysis allowed us to achieve the objective of verifying the relation between parity and RA risk. Second, some studies 14, 31, 35 did not control for important confounders and risk factors. Our results should be accepted with a comprehensive understanding. Thus, further welldesigned cohorts are warranted to confirm our findings. 58 Third, most of the participants in the included studies were American or European; thus, the results of our meta-analysis may be most applicable among similar populations 58, 59 and the extrapolation of these data to other populations should be performed with caution. Fourth, only a single study stratified risk by rheumatoid factor status and no significant relation was identified with either subset. Similarly, only one study evaluated risk by Anti-citrullinated protein antibodies (ACPA) status. Hence, further prospective cohort studies are required to evaluate cases by rheumatoid factor status and ACPA status, to better discern what risk factors are important in RA subset pathogenesis.
Clinical implication
The findings of this study have some potential implications for public health and clinical practice. Regarding public health messages, our findings on parity and RA risk may contribute to identifying women at lower risk of developing RA, and entering these subjects into a surveillance program for RA during a woman's fertile years possibly improves their clinical outcomes. Meanwhile, the present study also enhances our understanding of the risk factors of RA. In terms of clinical practice, these benefits seem to encourage childbearing. Parity may reduce the risk of RA, especially up to two children. Furthermore, parity may be more beneficial to women who possess the SE or lack the DERAA sequence in their HLA-genotype. Similarly, higher parity may be associated with a decreased risk of bladder, 60 endometrial, 61 and pancreatic cancer; 62 however, it should be noted that parity is known to be associated with increased risks of gallbladder cancer 9 and type II diabetes. 63 Therefore, clinicians should weigh carefully the inferred benefits of parity against risks involved for a particular patient before making a formal decision.
In summary, our study suggests a J-shaped relation between parity and RA risk, which suggests that parity is associated with a reduced risk of RA. The reduced risk was pronounced at the level of two live births. Further studies are warranted to confirm our findings.
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